<!DOCTYPE html><html><head><meta charSet="utf-8" class="next-head"/><title class="next-head">ALiEM Cards</title><meta name="viewport" content="initial-scale=1.0, width=device-width" class="next-head"/><meta charset="utf-8" class="next-head"/><meta http-equiv="x-ua-compatible" content="ie=edge" class="next-head"/><link rel="apple-touch-icon" sizes="180x180" href="/static/Favicons/apple-touch-icon.png" class="next-head"/><link rel="icon" type="image/png" href="/static/Favicons/favicon-32x32.png" sizes="32x32" class="next-head"/><link rel="icon" type="image/png" href="/static/Favicons/favicon-16x16.png" sizes="16x16" class="next-head"/><link rel="mask-icon" href="/static/Favicons/safari-pinned-tab.svg" color="#00b092" class="next-head"/><link rel="shortcut icon" href="/static/Favicons/favicon.ico" class="next-head"/><link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Open+Sans" class="next-head"/><link rel="preload" href="/_next/static/1~ee3OFOv6kXxZUoU_eCb/pages/card.js" as="script"/><link rel="preload" href="/_next/static/1~ee3OFOv6kXxZUoU_eCb/pages/_app.js" as="script"/><link rel="preload" href="/_next/static/1~ee3OFOv6kXxZUoU_eCb/pages/_error.js" as="script"/><link rel="preload" href="/_next/static/runtime/webpack-89179faa512dd01fbb62.js" as="script"/><link rel="preload" href="/_next/static/chunks/commons.ce4c8f8c27f9b1d9e256.js" as="script"/><link rel="preload" href="/_next/static/chunks/styles.9b76ae77785496d5351a.js" as="script"/><link rel="preload" href="/_next/static/runtime/main-cfdfd101abde4b1d3f2a.js" as="script"/><link rel="stylesheet" href="/_next/static/css/commons.b3e9c004.chunk.css"/><link rel="stylesheet" href="/_next/static/css/styles.0fc85b66.chunk.css"/></head><body><div id="__next"><div data-reactroot=""><div><div class="header" role="banner"><div class="header__logo"><a href="/"><img src="/static/logo.svg"/></a></div><div class="header__nav-button"><button class="hamburger hamburger__squeeze"><span class="hamburger__box"><span class="hamburger__inner"></span></span></button></div><nav class="header__nav header__nav--closed" role="navigation"><ul><li><a href="/cards/">Cards</a></li><li><a href="/categories/">Categories</a></li><li><a href="/about/">About</a></li></ul></nav></div><div class="search"><div class="search__input" role="search"><input type="text" placeholder="Search" aria-label="Search for cards" value=""/></div></div></div><main class="content container" role="main"><article role="article"><h1>Ectopic Pregnancy and Methotrexate</h1><div class="card"><div class="card__meta"><div><strong>Author: </strong>Michelle Lin, MD</div><div><strong>Updated:</strong> <!-- -->11/11/2011</div></div><div class="card__content"><h1 id="methotrexate-for-ectopic-pregnancy">Methotrexate for Ectopic Pregnancy</h1>
<h2 id="methotrexate-mtx-">Methotrexate (MTX)</h2>
<p><strong>Background</strong></p>
<ul>
<li>Dihydrofolate reductase inhibitor</li>
<li>Overall success rate for treating ectopic pregnancy = 71-94%</li>
<li>Success rate of single-dose MTX for beta-hCG &gt;5,000 mIU/mL = 85.7% </li>
</ul>
<p><strong>Side Effects</strong></p>
<ul>
<li>Abdominal pain</li>
<li>Nausea/vomiting</li>
<li>Stomatitis    </li>
</ul>
<h2 id="eligibility-contraindications-for-mtx-in-ectopic-pregnancy">Eligibility / Contraindications for MTX in Ectopic Pregnancy</h2>
<p><strong>Eligibility Criteria: (Need to fulfill all criteria)</strong></p>
<ul>
<li>High clinical suspicion or confirmed ectopic pregnancy</li>
<li>Hemodynamically stable</li>
<li>Unruptured mass</li>
<li>Able to comply with close follow-up</li>
<li>Normal creatinine, liver transaminases, WBC, hematocrit, and platelet counts </li>
</ul>
<p><strong>Contraindications:</strong></p>
<ul>
<li>Breastfeeding</li>
<li>Overt or lab evidence of immunodeficiency</li>
<li>Alcoholism, alcoholic or chronic liver disease</li>
<li>Preexisting blood dyscrasias or significant anemia </li>
<li>Known sensitivity to MTX</li>
<li>Active pulmonary disease</li>
<li>Peptic ulcer disease</li>
<li>Hepatic, renal, or hematologic dysfunction</li>
<li>Gestational sac &gt;3.5 cm on U/S (relative contraindication) </li>
<li>Embryonic cardiac motion on U/S (relative contraindication) </li>
</ul>
<h2 id="single-dose-regimen">Single-Dose Regimen</h2>
<ul>
<li>Day 1: <span class="drug">Methotrexate</span> 50 mg/m2 IM</li>
</ul>
<p><strong>Follow up with obstetrician:</strong></p>
<ul>
<li>Days 4 and 7: Measure beta-hCG</li>
<li>Between Days 4 and 7: Check for 15% beta-hCG decrease</li>
<li>Measure beta-hCG weekly until non-pregnant level</li>
<li>If beta-hCG dose not decrease by &gt;15% as expected, re-dose 50 mg/m2 IM and repeat B-hCG on days 4 and 7 after 2nd dose. </li>
</ul>
<h2 id="alternative-regimens">Alternative Regimens</h2>
<ul>
<li><strong>Two-Dose</strong> and <strong>Fixed Multidose</strong> regimens available as proposed by ACOG guidelines - Consider for beta-hCG level &gt;5,000 mIU/mL</li>
</ul>
<h2 id="references">References</h2>
<ul>
<li>ACOG Practice Bulletin No. 94:Medical management of ectopic pregnancy. Obstet Gynecology. 2008; 111(6):1479-85. [<a href="http://www.ncbi.nlm.nih.gov/pubmed/18515537">PubMed</a>]</li>
</ul>
</div></div></article></main><div class="footer" role="contentinfo"><div class="container"><div class="row footer__cc"><div class="footer__cc-image"><a rel="license" href="http://creativecommons.org/licenses/by-nc-nd/3.0/"><img alt="creative-commons" src="/static/by-nc-nd.svg"/></a></div><div class="footer__cc-text">This work is licensed under a<!-- --> <a rel="license" href="http://creativecommons.org/licenses/by-nc-nd/3.0/">Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License</a>.</div></div><div class="row footer__links"><div><a href="/contact/">Contact</a></div><div><a href="/contact/">Get Involved</a></div><div><a href="/about/">About</a></div></div><div class="row row--centered"><div class="container footer__disclaimer">ALiEM Cards content is intended for use by healthcare professionals. Users of this site should exercise their own clinical judgment as to the reliability and accuracy of its information. Non-healthcare-professionals who use this site do so at their own risk. Content on this site should not be construed as medical advice. Users should always confer with medical profoessionals regarding decisions about medications, evaluations and other medical treatments.</div></div></div></div></div></div><script>__NEXT_DATA__ = {"props":{"pageProps":{"card":{"slug":"ectopic-methotrexate","title":"Ectopic Pregnancy and Methotrexate","authors":["Michelle Lin, MD"],"categories":[{"slug":"obgyn","name":"OBGYN"}],"created":"2011/11/11","updated":null,"body":"\n# Methotrexate for Ectopic Pregnancy\n\n## Methotrexate (MTX)\n\n**Background**\n\n- Dihydrofolate reductase inhibitor\n- Overall success rate for treating ectopic pregnancy = 71-94%\n- Success rate of single-dose MTX for beta-hCG \u003e5,000 mIU/mL = 85.7% \n\n**Side Effects**\n\n- Abdominal pain\n- Nausea/vomiting\n- Stomatitis    \n\n## Eligibility / Contraindications for MTX in Ectopic Pregnancy\n\n**Eligibility Criteria: (Need to fulfill all criteria)**\n\n- High clinical suspicion or confirmed ectopic pregnancy\n- Hemodynamically stable\n- Unruptured mass\n- Able to comply with close follow-up\n- Normal creatinine, liver transaminases, WBC, hematocrit, and platelet counts \n\n**Contraindications:**\n\n- Breastfeeding\n- Overt or lab evidence of immunodeficiency\n- Alcoholism, alcoholic or chronic liver disease\n- Preexisting blood dyscrasias or significant anemia \n- Known sensitivity to MTX\n- Active pulmonary disease\n- Peptic ulcer disease\n- Hepatic, renal, or hematologic dysfunction\n- Gestational sac \u003e3.5 cm on U/S (relative contraindication) \n- Embryonic cardiac motion on U/S (relative contraindication) \n\n## Single-Dose Regimen\n\n- Day 1: \u003cspan class=\"drug\"\u003eMethotrexate\u003c/span\u003e 50 mg/m2 IM\n\n**Follow up with obstetrician:**\n\n- Days 4 and 7: Measure beta-hCG\n- Between Days 4 and 7: Check for 15% beta-hCG decrease\n- Measure beta-hCG weekly until non-pregnant level\n- If beta-hCG dose not decrease by \u003e15% as expected, re-dose 50 mg/m2 IM and repeat B-hCG on days 4 and 7 after 2nd dose. \n\n## Alternative Regimens\n\n- **Two-Dose** and **Fixed Multidose** regimens available as proposed by ACOG guidelines - Consider for beta-hCG level \u003e5,000 mIU/mL\n\n## References\n\n- ACOG Practice Bulletin No. 94:Medical management of ectopic pregnancy. Obstet Gynecology. 2008; 111(6):1479-85. [[PubMed](http://www.ncbi.nlm.nih.gov/pubmed/18515537)]\n"}}},"page":"/card","pathname":"/card","query":{"slug":"ectopic-methotrexate"},"buildId":"1~ee3OFOv6kXxZUoU_eCb","nextExport":true};__NEXT_LOADED_PAGES__=[];__NEXT_REGISTER_PAGE=function(r,f){__NEXT_LOADED_PAGES__.push([r, f])}</script><script async="" id="__NEXT_PAGE__/card" src="/_next/static/1~ee3OFOv6kXxZUoU_eCb/pages/card.js"></script><script async="" id="__NEXT_PAGE__/_app" src="/_next/static/1~ee3OFOv6kXxZUoU_eCb/pages/_app.js"></script><script async="" id="__NEXT_PAGE__/_error" src="/_next/static/1~ee3OFOv6kXxZUoU_eCb/pages/_error.js"></script><script src="/_next/static/runtime/webpack-89179faa512dd01fbb62.js" async=""></script><script src="/_next/static/chunks/commons.ce4c8f8c27f9b1d9e256.js" async=""></script><script src="/_next/static/chunks/styles.9b76ae77785496d5351a.js" async=""></script><script src="/_next/static/runtime/main-cfdfd101abde4b1d3f2a.js" async=""></script></body></html>